Security key
23255M204
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN)
CUSIP: 23255M204
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, no par value
- Shares outstanding
- 3,367,000
- Total 13F shares
- 258,836
- Share change
- -103,980
- Total reported value
- $595,353
- Price per share
- $2.30
- Number of holders
- 17
- Value change
- -$333,887
- Number of buys
- 5
- Number of sells
- 6
Report period
Q3 2025
Institutions
17
Top holders
10
CYCN full security history
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Cyclerion Therapeutics, Inc. SEC filings
Cyclerion Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 23255M204
Recent filing periods:
Top shareholders of CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Peter M. Hecht |
13D/G
3/4/5
|
Director, 10%+ Owner |
28%
|
1,028,086
|
$3,803,918 | $0 | 25 Mar 2025 | |
| J. WOOD CAPITAL ADVISORS LLC |
13D/G
|
— |
5.4%
|
181,818
|
$496,363 | $0 | 25 Mar 2025 | |
| American Endowment Foundation |
13D/G
|
— |
4.9%
|
133,026
|
$492,196 | $0 | 31 Dec 2024 | |
| TYNDALL CAPITAL PARTNERS L P |
13D/G
13F
|
Company |
4.8%
|
155,187
|
$487,287 | -$30,113 | 30 Jun 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
0.2%
|
4,740
|
$17,538 | $0 | 31 Dec 2024 | |
| Siren, L.L.C. |
13F
|
Individual |
3.4%
|
116,155
|
$338,011 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.97%
|
32,735
|
$95,288 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.7%
|
23,490
|
$68,356 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.5%
|
16,797
|
$48,879 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.29%
|
9,727
|
$28,306 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.08%
|
2,763
|
$8,040 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
649
|
$1,889 | — | 30 Jun 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.01%
|
192
|
$559 | — | 30 Jun 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
130
|
$378 | — | 30 Jun 2025 | |
| Activest Wealth Management |
13F
|
Company |
0%
|
100
|
$291 | — | 30 Jun 2025 | |
| MAI Capital Management |
13F
|
Company |
0%
|
100
|
$291 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
24
|
$70 | — | 30 Jun 2025 | |
| Pandora Wealth, Inc. |
13F
|
Company |
0%
|
11
|
$32 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
11
|
$32 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
5
|
$15 | — | 30 Jun 2025 | |
| Regina M. Graul |
3/4/5
|
President and Chief Executive Officer, Director |
—
mixed-class rows
|
156,152
mixed-class rows
|
$340,529 | — | 05 Aug 2024 | |
| Terrance McGuire |
3/4/5
|
Director |
—
class O/S missing
|
42,010
|
$142,624 | — | 30 Nov 2023 | |
| Errol B. Desouza |
3/4/5
|
Director |
—
class O/S missing
|
30,000
|
$101,850 | — | 30 Nov 2023 | |
| Michael J. Higgins |
3/4/5
|
Director |
—
class O/S missing
|
30,740
|
$84,535 | — | 25 Mar 2025 | |
| Dina Katabi |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
$67,900 | — | 30 Nov 2023 | |
| Steven Hyman |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
$67,900 | — | 30 Nov 2023 | |
| Andreas Busch |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Anjeza Gjino |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Cheryl Gault |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
135,000
|
— | — | 20 Jan 2022 | |
| Rhonda M. Chicko |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
25,000
|
— | — | 07 Aug 2025 | |
| George H. Conrades |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Marsha Fanucci |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Michael Mendelsohn |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Ole Isacson |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Stephanie Lovell |
3/4/5
|
Director |
—
class O/S missing
|
20,000
|
— | — | 14 Jun 2022 | |
| Kevin Churchwell |
3/4/5
|
Director |
—
class O/S missing
|
10,000
|
— | — | 24 Jun 2021 |
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q3 2025
As of 30 Sep 2025,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
258,836 shares.
The largest 10 holders included
Siren, L.L.C., DRW Securities, LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock, Inc., TWO SIGMA INVESTMENTS, LP, FMR LLC, Tower Research Capital LLC (TRC), MORGAN STANLEY, and GROUP ONE TRADING LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
17
Q3 2025 holders
17
Holder diff
0
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.